The chart tells the story. It was left for dead because both the 510k and patent were rejected around November beating it down to trips, low dubs. The patent was revived and that's what gave it a boost.
They can't sell the product without FDA clearance. That's critical information that shareholders and new investors have the right to know.
It's dead money waiting for the 510k approval which could take many months to years.
News 
Market Data 
Discover 
